Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Edwards Lifesciences (EW) to $80 from $90 and keeps an Overweight rating on the shares. The firm is updating its Edwards Lifesciences model following completion of the sale of Critical Care to Becton Dickinson (BDX) and the $1B of announced share buybacks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences says EPS lower in 2025 than in 2024
- Edwards Lifesciences down 6% as company presents at Wells Fargo conference
- Edwards Lifesciences Enhances Shareholder Value Post-Divestiture
- Becton Dickinson completes purchase of Critical Care from Edwards Lifesciences
- Edwards Lifesciences call volume above normal and directionally bullish